Issue 10, 2021

Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors

Abstract

Tragically, the death toll from the COVID-19 pandemic continues to rise, and with variants being observed around the globe new therapeutics, particularly direct-acting antivirals that are easily administered, are desperately needed. Studies targeting the SARS-CoV-2 3CL protease, which is critical for viral replication, with different peptidomimetics and warheads is an active area of research for development of potential drugs. To date, however, only a few publications have evaluated the nitrile warhead as a viral 3CL protease inhibitor, with only modest activity reported. This article describes our investigation of P3 4-methoxyindole peptidomimetic analogs with select P1 and P2 groups with a nitrile warhead that are potent inhibitors of SARS-CoV-2 3CL protease and demonstrate in vitro SARS-CoV-2 antiviral activity. A selectivity for SARS-CoV-2 3CL protease over human cathepsins B, S and L was also observed with the nitrile warhead, which was superior to that with the aldehyde warhead. A co-crystal structure with SARS-CoV-2 3CL protease and a reversibility study indicate that a reversible, thioimidate adduct is formed when the catalytic sulfur forms a covalent bond with the carbon of the nitrile. This effort also identified efflux as a property limiting antiviral activity of these compounds, and together with the positive attributes described these results provide insight for further drug development of novel nitrile peptidomimetics targeting SARS-CoV-2 3CL protease.

Graphical abstract: Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors

Supplementary files

Article information

Article type
Research Article
Submitted
22 srp 2021
Accepted
20 kol 2021
First published
20 kol 2021

RSC Med. Chem., 2021,12, 1722-1730

Author version available

Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors

B. Bai, E. Arutyunova, M. B. Khan, J. Lu, M. A. Joyce, H. A. Saffran, J. A. Shields, A. S. Kandadai, A. Belovodskiy, M. Hena, W. Vuong, T. Lamer, H. S. Young, J. C. Vederas, D. L. Tyrrell, M. J. Lemieux and J. A. Nieman, RSC Med. Chem., 2021, 12, 1722 DOI: 10.1039/D1MD00247C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements